Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.

In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...

Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

A blood test that measures elevations in neurofilament light chain (NfL) levels in patients with multiple sclerosis (MS) could warn of worsening disability up to 2 years before it occurs, a new study ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) ...

In people with active secondary progressive multiple sclerosis (MS), hematopoietic stem cell transplants may delay disability longer than some other MS medications, according to a new study. The study ...